DXCM vs LMAT: fair value comparison
DexCom, Inc. and LeMaitre Vascular, Inc. · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, DXCM currently sits closer to the top of our discount ranking. LMAT carries the stronger quality grade.
| DXCM | LMAT | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $83.03 | $81.08 |
| 12-month range | $58.22–$90.14 | $79.54–$111.42 |
| Sector rank | #19 of 113 Healthcare | #23 of 113 Healthcare |
| Quality grade | B | A |
| Momentum grade | B | — |
| Leverage | Moderate | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | Strong | Strong |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Uptrend | Downtrend |
| DCF cross-check | Overvalued | Undervalued |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: DXCM fair value analysis · LMAT fair value analysis